Core Viewpoint - Aikoreis Bio-Pharmaceutical Co., Ltd. has secured several million yuan in financing to accelerate the clinical trials of its ACR246 project and other ADC drug preclinical research [1] Group 1 - Aikoreis completed an investment signing ceremony with Shaoxing Ruike Enterprise Management Co., Ltd. in Hangzhou on August 22 [1] - The financing will primarily be used for advancing the clinical Ib/IIa trials of the ACR246 project [1] - The funds will also support preclinical research for other ADC drugs [1]